Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Smokey1958on Nov 22, 2021 7:11am
674 Views
Post# 34151834

Fantastic Article....

Fantastic Article....

....and why approval of AcuVid still has incredible potential.

The following opinion piece describes the reasons behind the shortfall in the availability of rapid antigen tests in the US. Written in the last 24 hours it also outlines how these tests continue to be readily available and used in many European countries. Clearly as supply is not yet meeting demand there is lots of opportunity for THRMs easy to use, accurate and inexpensive AcuVid to fill in the gap. 

https://nymag.com/intelligencer/article/at-home-covid-tests-accuracy-supply-issues.html

Rob projected in the October NR that the completion of testing would take 2 to 3 weeks including a few days to receive IRB approval. As that took longer than expected it has been 9 days since approval was granted. The summary overview of the testing process suggested an end date sometime in December. That study sites have been organized suggests testing has probably already commenced.  

Imho if testing is completed and FDA EUA is granted before Christmas THRM will easily see $1.00. If Rob can announce timing for production of tests and some initial contracts early in the new year it could become a 10x bagger (from its current sp) much sooner than expected.

From an accuracy perspective AcuVid has weathered all the challenges from new variants to increased expectations from the FDA. Hopefully this final roadblock meets with the same positive outcome.

GLTE ...holding patiently!!!

<< Previous
Bullboard Posts
Next >>